
New gene therapy considered cure for Sickle Cell Disease being administered at St. Louis Children’s Hospital
ST. LOUIS, Mo. (First Alert 4) - A gene therapy recently approved by the FDA to treat patients with Sickle Cell Anemia is now being administered in St. Louis. In 2023, the FDA approved Lyfgenia, developed by Bluebird Bio, a bio-tech company specializing in …